Search - tctmd.com

Displaying 1 - 20 of 87

Sort: Relevancy | Date

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

News Daily News

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

Michael O'Riordan

July 25, 2023

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

Todd Neale

November 10, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Shelley Wood

September 22, 2022

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Shelley Wood

September 07, 2022

News Conference News EAS 2022

Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively

Michael O'Riordan

May 27, 2022

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

News Conference News ACC 2022

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Michael O'Riordan

April 06, 2022

Advertisement

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

What’s Going to Be Hot at TCT 2025

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

SCAAR Registry Delves Into Left Main Revascularization Outcomes

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content